Deejesh Subramanian1, Cintia V Cruz2,3, Facundo Garcia-Bournissen4. 1. Schulich School of Medicine and Dentistry (DS), University of Western Ontario, London, Ontario, Canada. 2. Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine (CVC), Mahidol University, Bangkok, Thailand. 3. Laboratory of Applied Statistics in Health Sciences (LEACS), Department of Toxicology and Pharmacology, Medical School (CVC), University of Buenos Aires, Buenos Aires, Argentina. 4. Division of Pediatric Clinical Pharmacology, Department of Pediatrics (FG-B), Schulich School of Medicine & Dentistry, University of Western Ontario, Victoria Hospital, London Health Sciences Centre, London, Ontario, Canada.
Abstract
OBJECTIVE: Children have generally been excluded from early-stage clinical trials owing to safety concerns based in social expectations and not data. However, the repositioning of adult therapeutics for pediatric use and the increase in the development of therapies for pediatric only conditions require the participation of children in phase 1-2 trials. Therefore, the aim of this article is to systematically review the history and current state of early phase pediatric clinical pharmacology trials in order to understand safety concerns, trends, and challenges in pediatric trials. METHODS: This review analyzed the nature of early phase pediatric clinical trials conducted for nononcology conditions through a systematic search that was performed for pediatric non-oncologic phase 1 or phase 1-2 drug and vaccine studies in MEDLINE. RESULTS: The data show that the number of early phase pediatric clinical trials is still small relative to adults but has been on the rise in the past decade with relatively few serious adverse effects observed. CONCLUSIONS: The widespread concerns about children's safety when they participate in early phase clinical trials seem disproportionate, based on our findings. The data confirm that these studies can be conducted safely, and that their results can contribute significantly to pediatric pharmacotherapy. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.
OBJECTIVE: Children have generally been excluded from early-stage clinical trials owing to safety concerns based in social expectations and not data. However, the repositioning of adult therapeutics for pediatric use and the increase in the development of therapies for pediatric only conditions require the participation of children in phase 1-2 trials. Therefore, the aim of this article is to systematically review the history and current state of early phase pediatric clinical pharmacology trials in order to understand safety concerns, trends, and challenges in pediatric trials. METHODS: This review analyzed the nature of early phase pediatric clinical trials conducted for nononcology conditions through a systematic search that was performed for pediatric non-oncologic phase 1 or phase 1-2 drug and vaccine studies in MEDLINE. RESULTS: The data show that the number of early phase pediatric clinical trials is still small relative to adults but has been on the rise in the past decade with relatively few serious adverse effects observed. CONCLUSIONS: The widespread concerns about children's safety when they participate in early phase clinical trials seem disproportionate, based on our findings. The data confirm that these studies can be conducted safely, and that their results can contribute significantly to pediatric pharmacotherapy. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.
Entities:
Keywords:
drug trials; early phase pediatric clinical trials; pediatric clinical pharmacology; phase 1; phase 1–2; vaccine trials
Authors: Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry Journal: Pediatr Infect Dis J Date: 2017-01 Impact factor: 2.129
Authors: Brahm Goldstein; Simon Nadel; Mark Peters; Roger Barton; Flavia Machado; Howard Levy; Douglas J Haney; Barbara Utterback; Mark D Williams; Brett P Giroir Journal: Pediatr Crit Care Med Date: 2006-05 Impact factor: 3.624
Authors: Carolyn M Bennett; Zora R Rogers; Daniel D Kinnamon; James B Bussel; Donald H Mahoney; Thomas C Abshire; Hadi Sawaf; Theodore B Moore; Mignon L Loh; Bertil E Glader; Maggie C McCarthy; Brigitta U Mueller; Thomas A Olson; Adonis N Lorenzana; William C Mentzer; George R Buchanan; Henry A Feldman; Ellis J Neufeld Journal: Blood Date: 2005-12-13 Impact factor: 22.113
Authors: Mark Mirochnick; Taha Taha; Regis Kreitchmann; Karin Nielsen-Saines; Newton Kumwenda; Esau Joao; Jorge Pinto; Breno Santos; Teresa Parsons; Brian Kearney; Lynda Emel; Casey Herron; Paul Richardson; Sarah E Hudelson; Susan H Eshleman; Kathleen George; Mary G Fowler; Paul Sato; Lynne Mofenson Journal: J Acquir Immune Defic Syndr Date: 2014-01-01 Impact factor: 3.731
Authors: Frank Kloprogge; Lesley Workman; Steffen Borrmann; Mamadou Tékété; Gilbert Lefèvre; Kamal Hamed; Patrice Piola; Johan Ursing; Poul Erik Kofoed; Andreas Mårtensson; Billy Ngasala; Anders Björkman; Michael Ashton; Sofia Friberg Hietala; Francesca Aweeka; Sunil Parikh; Leah Mwai; Timothy M E Davis; Harin Karunajeewa; Sam Salman; Francesco Checchi; Carole Fogg; Paul N Newton; Mayfong Mayxay; Philippe Deloron; Jean François Faucher; François Nosten; Elizabeth A Ashley; Rose McGready; Michele van Vugt; Stephane Proux; Ric N Price; Juntra Karbwang; Farkad Ezzet; Rajesh Bakshi; Kasia Stepniewska; Nicholas J White; Philippe J Guerin; Karen I Barnes; Joel Tarning Journal: PLoS Med Date: 2018-06-12 Impact factor: 11.069